Work on the Cell Biology Seven advances
Current members ARE....BTX ARWR ISCO MEDS AMBS

I am not prepared to make BUY CALLS on these issues. I am prepared to tell the BIOWAVE readership and especially the subgroup I call the EARLYBIRDS who are known to want to join me in discussing WHAT IS NEXT scenarios that it is TIME to take a TOE IN THE WATER position. Doing that will force you to PAY ATTENTION as these firms advance their research programs.
My target for the timing of Capital Appreciation in the cell biology seven is 2016 to 2020. I expect the members of the MAGNIFICENT SEVEN to have peaked by 2016. Most of them will have achieved FDA approval by that time and thus be considered "BIG PHARMA"